ChromoGenics AB (publ): Bulletin from the annual general meeting held on 25 June 2024

ChromoGenics AB ("ChromoGenics" or the "Company") has today, on 25 June 2024, held its annual general meeting. The annual general meeting in ChromoGenics resolved, among other things, as follows. The notice to the annual general meeting and the complete proposals are available on the Company's website, www.chromogenics.com.

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director

The annual general meeting resolved to approve the profit and loss accounts and balance sheets for the financial year 2023 and the persons who have been board members and managing directors were discharged from liability with respect to their respective management of the Company for the financial year 2023.

Allocation of the Company’s profit or loss

The annual general meeting resolved, in accordance with the board of directors’ proposal, that the Company’s results should be carried forward.

Board of directors and auditor

The annual general meeting resolved, in accordance with the nomination committee’s proposal, that the Company's board of directors shall consist of five board members with no deputy board members and that the Company shall have one auditor with no deputies.

Further, the annual general meeting resolved, in accordance with the nomination committee’s proposal, to re-elect Johan Hedin, Anders Brännström, Andreas Jaeger, Fredrik Andersson and Sirpa Engman as board members, all for the period until the end of the next annual general meeting. It was further resolved, in accordance with the nomination committee’s proposal, to re-elect Johan Hedin as chairman of the board of directors for the period until the end of the next annual general meeting.

The annual general meeting resolved, in accordance with the nomination committee’s proposal, to re-elect PricewaterhouseCoopers AB as the Company’s auditor, for the period until the end of the next annual general meeting, currently with Niclas Bergenmo as auditor in charge.

Remuneration

The annual general meeting resolved, in accordance with the nomination committee’s proposal, that the remuneration for the board of directors, for the period until the end of the next annual general meeting, shall remain unchanged. It was resolved that the chairman of the board of directors shall receive SEK 200,000 and that the other board members shall receive SEK 100,000 each.

The annual general meeting also resolved, in accordance with the nomination committee’s proposal, that remuneration to the auditor shall be paid according to approved invoices.

Amendments to the articles of associations

The annual general meeting resolved, in accordance with the board of directors' proposal, to amend the limits for the share capital in § 4 and for the number of shares in § 5 of the articles of association. The annual general meeting resolved that the Company's share capital shall be not less than SEK 36,000,000 and not more than SEK 144,000,0000 (previously not less than SEK 22,000,000 and not more than SEK 88,000,000) and that the number of shares shall be not less than 6,000,000 and not more than 24,000,000 (previously not less than 4,000,000 and not more than 16,000,000).

Issue authorisation

The annual general meeting resolved, in accordance with the board of directors’ proposal, to authorise the board of directors, on one or several occasions and for the period up to the next annual general meeting, to resolve to issue new shares, warrants and/or convertibles, with or without deviation from the shareholders’ pre-emptive rights. The number of shares that may be issued and the number of shares to which conversion/subscription may be made shall be accommodated within the limits of the articles of association applicable from time to time. The purpose of the authorisation is to provide flexibility to the board of directors in its work to ensure that the Company in an appropriate manner can raise capital and acquire companies, businesses, and other assets.

For more information, please contact:

Fredrik Fränding, CEO
Anne-Marie Gullman, CFO & Head of Investor Relations
Tel: +46 (0) 18 430 0430

E-mail: [email protected]

About this information

The information was submitted for publication, through the agency of the contact persons set out above, at 13:45 CEST on 25 June 2024.

About ChromoGenics

ChromoGenics is a proptech company that produces smart dynamic glass, improving indoor environment and well-being while reducing energy consumption, operational costs, and climate impact in real estate. The product, ConverLight® dynamic glass, is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic films. The result is a dynamic foil that can be laminated into glass, providing effective sun protection in buildings and reducing environmental impact in production, transportation, and usage. The dynamic foil is easy to transport and can be applied by local partners in the glass industry, avoiding the need for long-distance shipments of bulky glass. All products from ChromoGenics prioritize environmental and health aspects, focusing on eco-friendly materials, reduced energy consumption, increased access to daylight and views, and improved indoor comfort.

ChromoGenics' production facility in Uppsala has been partly financed through conditional loans from the Swedish Energy Agency. ChromoGenics' stock (CHRO) is listed on the Nasdaq First North Growth Market, with Vator Securities serving as the Certified Adviser.